Document is current
Any future updates will be listed below
-
Authors
Tsai, Yo-Ting https://orcid.org/0000-0002-7556-1633
Strauss, Julius https://orcid.org/0000-0002-7550-4938
Toney, Nicole J https://orcid.org/0000-0003-4181-5647
Jochems, Caroline https://orcid.org/0000-0002-9000-9855
Venzon, David J
Gulley, James L https://orcid.org/0000-0002-6569-2912
Schlom, Jeffrey https://orcid.org/0000-0001-7932-4072
Donahue, Renee N https://orcid.org/0000-0002-6828-3073
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02517398 at ClinicalTrials.govnct03427411 at ClinicalTrials.govDocuments that mention this clinical trial
116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
https://doi.org/10.1007/s11523-021-00809-2
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
480 Investigating genetic predisposition to immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-sitc2024.0480
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy
https://doi.org/10.1136/jitc-2024-009702
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
https://doi.org/10.1007/s12325-019-01018-0
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-008480
nct02517398 at ClinicalTrials.govDocuments that mention this clinical trial
116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8
44 Early kinetics of circulating tumor HPV-16 and HPV-18 DNA are associated with survival in patients with HPV-associated cancers treated with dual blockade of PD-L1 and TGF-β
https://doi.org/10.1136/jitc-2025-sitc2025.0044
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
https://doi.org/10.1136/jitc-2021-003113
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006
nct03427411 at ClinicalTrials.govDocuments that mention this clinical trial
116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
https://doi.org/10.1007/s11523-021-00809-2
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
480 Investigating genetic predisposition to immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-sitc2024.0480
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy
https://doi.org/10.1136/jitc-2024-009702
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
https://doi.org/10.1007/s12325-019-01018-0
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-008480
nct03631706 at ClinicalTrials.govDocuments that mention this clinical trial
116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8
44 Early kinetics of circulating tumor HPV-16 and HPV-18 DNA are associated with survival in patients with HPV-associated cancers treated with dual blockade of PD-L1 and TGF-β
https://doi.org/10.1136/jitc-2025-sitc2025.0044
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
https://doi.org/10.1136/jitc-2021-003113
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006
nct03840902 at ClinicalTrials.govDocuments that mention this clinical trial
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
Retrospective clinical analysis of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC).
https://doi.org/10.1200/jco.2023.41.16_suppl.9098
nct04066491 at ClinicalTrials.govDocuments that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
nct02517398 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
Documents that mention this clinical trial
116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
https://doi.org/10.1007/s11523-021-00809-2
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
480 Investigating genetic predisposition to immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-sitc2024.0480
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy
https://doi.org/10.1136/jitc-2024-009702
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
https://doi.org/10.1007/s12325-019-01018-0
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-008480
- License Information
